Program
Cetylpyridinium
Also written as “Cetylpyridinium chloride”, “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash” and “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”.
Its studies are mostly in Gingivitis · Dental Plaque · Pharyngitis · Diabetes Mellitus, Type 2 · Onychomycosis, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmolive | 61 open or running | phase 4since Feb 6, 2015 | Jul 15, 2014 | Jan 2, 2028phase 4 · NCT07619729 |
| Procter and Gamble | 20 open or running | phase 4since Sep 29, 2025 | Feb 28, 2012 | none ahead |
| Sanofi | 20 open or running | phase 3since May 27, 2008 | May 27, 2008 | none ahead |
| Valenta Pharm JSC | 22 open or running | phase 1since Feb 17, 2025 | Feb 17, 2025 | Dec 1, 2026phase 1 · NCT06859281 |
| Angelini Pharma | 10 open or running | phase 1since Apr 27, 2018 | Apr 27, 2018 | none ahead |
| NanoBio | 10 open or running | phase 2since Mar 26, 2007 | Mar 26, 2007 | none ahead |
| Suzhou Neologics Bioscience | 11 open or running | phase 1since May 25, 2023 | May 25, 2023 | none ahead |
Also a collaborator on its studies: Cross Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2007First study: phase 2 study in OnychomycosisNew to NanoBioNanoBio · NCT00453271 · 443 enrolled · United States, Canada
- May 27, 2008Sanofi's first study: phase 3 study in HealthyNew to SanofiSanofi · NCT00687037 · 30 enrolled · Brazil
- Aug 4, 2008Phase 3 study in HygieneSanofi · NCT00729599 · 31 enrolled · Brazil
- Feb 28, 2012Procter and Gamble's first study: no phase study in GingivitisNew to Procter and GambleProcter and Gamble · NCT01549587 · 746 enrolled · United States
- Jul 15, 2014Colgate Palmolive's first study: phase 3 study in Dental PlaqueNew to Colgate PalmoliveColgate Palmolive · NCT02193165 · 120 enrolled · Puerto Rico
- Feb 6, 20152 phase 4 studies in Dental PlaqueColgate Palmolive · NCT02366689, NCT02360995
- Apr 27, 2018Angelini Pharma's first study: phase 1 study in HealthyNew to Angelini PharmaAngelini Pharma · NCT03706781 · 26 enrolled · Switzerland
- May 25, 2023Suzhou Neologics Bioscience's first study: phase 1 study in Advanced Solid TumorNew to Suzhou Neologics BioscienceSuzhou Neologics Bioscience · NCT05924906 · 30 planned
- Jan 7, 2025Phase 3 study in GingivitisColgate Palmolive · NCT06770114 · 80 enrolled · Italy
- Feb 17, 2025Valenta Pharm JSC's first studies: 2 phase 1 studies in PharyngitisNew to Valenta Pharm JSCValenta Pharm JSC · NCT06859281, NCT06857890
- Sep 29, 2025Phase 4 study in GingivitisProcter and Gamble · NCT07211061 · 69 enrolled · United States
- Nov 24, 2025Phase 3 study in GingivitisColgate Palmolive · NCT07263698 · 80 enrolled · Italy
- May 26, 2026Phase 4 study in Diabetes Mellitus, Type 2Colgate Palmolive · NCT07619729 · 10,000 planned · United States
Ahead
- Dec 1, 2026Primary completion: phase 1 study in PharyngitisValenta Pharm JSC · NCT06859281
- Dec 1, 2026Primary completion: phase 1 study in PharyngitisValenta Pharm JSC · NCT06857890
- Jan 2, 2028Primary completion: phase 4 study in Diabetes Mellitus, Type 2Colgate Palmolive · NCT07619729
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07619729Diabetes Mellitus, Type 2 · United States | 4 | By invitation | Colgate Palmolive | Jan 2, 2028 | 10,000 |
| NCT07263698Gingivitis · Italy | 3 | Completed | Colgate Palmolive | Feb 27, 2026 | 80 |
| NCT07211061Gingivitis · United States | 4 | Completed | Procter and Gamble | Nov 10, 2011 | 69 |
| NCT06859281Pharyngitis · Russia | 1 | Recruiting | Valenta Pharm JSC | Dec 1, 2026 | 24 |
| NCT06857890Pharyngitis · Russia | 1 | Recruiting | Valenta Pharm JSC | Dec 1, 2026 | 24 |
| NCT06770114Gingivitis · Italy | 3 | Completed | Colgate Palmolive | May 9, 2022 | 80 |
| NCT05924906Advanced Solid Tumor | 1 | Not yet recruiting | Suzhou Neologics Bioscience | Apr 2026 | 30 |
| NCT03706781Healthy · Switzerland | 1 | Completed | Angelini Pharma | Dec 18, 2017 | 26 |
| NCT02366689Dental Plaque · United States | 4 | Completed | Colgate Palmolive | Dec 2014 | 179 |
| NCT02360995Dental Plaque · United States | 4 | Completed | Colgate Palmolive | Aug 2014 | 129 |
| NCT02193165Dental Plaque · Puerto Rico | 3 | Completed | Colgate Palmolive | Aug 2014 | 120 |
| NCT01549587Gingivitis · United States | – | Completed | Procter and Gamble | Feb 2014 | 746 |
| NCT00729599Hygiene · Brazil | 3 | Completed | Sanofi | Aug 2008 | 31 |
| NCT00687037Healthy · Brazil | 3 | Completed | Sanofi | Feb 2008 | 30 |
| NCT00453271Onychomycosis · United States, Canada | 2 | Completed | NanoBio | Oct 2008 | 443 |
How it is read
Names in the registry
- “Cetylpyridinium chloride”, 2 entries
- “Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash”, 1 entry
- “cetylpyridinium chloride (CPC), zinc lactate and sodium fluoride Mouthwash”, 1 entry
- “Cetylpyridinium Chloride, Zinc Lactate and Hyaluronic Acid Mouthwash”, 1 entry
- “Cetylpyridinium Chloride (CPC)”, 1 entry
Conditions, from the studies’ own filings
- Gingivitis, 4 studies
- Dental Plaque, 3 studies
- Pharyngitis, 2 studies
- Diabetes Mellitus, Type 2, 1 study
- Onychomycosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.